Re: Dutasteride in Localised Prostate Cancer Management: The REDEEM Randomised, Double-Blind, Placebo-Controlled Trial Editorial Comment

被引：5
作者：
Walsh, Patrick C.
机构：
来源：
JOURNAL OF UROLOGY | 2012年 / 188卷 / 01期
关键词：
SURVEILLANCE; INTERVENTION;
D O I：
10.1016/j.juro.2012.03.102
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：110 / 111
页数：2
相关论文
共 8 条
  • [1] [Anonymous], NCCN Clinical Practice Guidelines in Oncology - Breast Cancer
  • [2] FDA Drug Safety Communication, 5 ALPH RED INH 5 ARI
  • [3] Kolata G, 2012, NY TIMES 0123
  • [4] Comparing Prostate Specific Antigen Triggers for Intervention in Men With Stable Prostate Cancer on Active Surveillance
    Loblaw, Andrew
    Zhang, Liying
    Lam, Adam
    Nam, Robert
    Mamedov, Alexandre
    Vesprini, Danny
    Klotz, Laurence
    [J]. JOURNAL OF UROLOGY, 2010, 184 (05) : 1942 - 1946
  • [5] What (if anything) to do about low-risk prostate cancer
    Parker, Chris
    [J]. LANCET, 2012, 379 (9821) : 1078 - 1080
  • [6] Prostate-Specific Antigen Kinetics During Follow-Up Are an Unreliable Trigger for Intervention in a Prostate Cancer Surveillance Program
    Ross, Ashley E.
    Loeb, Stacy
    Landis, Patricia
    Partin, Alan W.
    Epstein, Jonathan I.
    Kettermann, Anna
    Feng, Zhaoyong
    Walsh, Patrick C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (17) : 2810 - 2816
  • [7] The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention
    Theoret, Marc R.
    Ning, Yang-Min
    Zhang, Jenny J.
    Justice, Robert
    Keegan, Patricia
    Pazdur, Richard
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (02) : 97 - 99
  • [8] US Food and Drug Administration, DEC 1 2010 M ONC DRU
1